Notice Pursuant to the National Cooperative Research and Production Act of 1993-UHD Alliance, Inc., 15175 [2018-07129]
Download as PDF
<![CDATA[
15175
Federal Register / Vol. 83, No. 68 / Monday, April 9, 2018 / Notices
Dated: April 3, 2018.
Elizabeth K. Appel,
Director, Office of Regulatory Affairs and
Collaborative Action—Indian Affairs.
[FR Doc. 2018–07122 Filed 4–6–18; 8:45 am]
BILLING CODE 4337–15–P
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National
Cooperative Research and Production
Act of 1993—UHD Alliance, Inc.
Notice is hereby given that, on March
8, 2018, pursuant to Section 6(a) of the
National Cooperative Research and
Production Act of 1993, 15 U.S.C. 4301
et seq. (‘‘the Act’’), UHD Alliance, Inc.
(‘‘UHD Alliance’’) filed written
notifications simultaneously with the
Attorney General and the Federal Trade
Commission disclosing changes in its
membership. The notifications were
filed for the purpose of extending the
Act’s provisions limiting the recovery of
antitrust plaintiffs to actual damages
under specified circumstances.
Specifically, Google, Inc., Mountain
View, CA; Teledyne LeCroy, Elgin, IL;
and Synaptics, San Jose, CA, have been
added as parties to this venture.
Also, HDAnywhere Ltd., Malvern,
UNITED KINGDOM; Quantum Data,
Inc., Elgin, IL; and Sky UK Ltd.,
Isleworth, UNITED KINGDOM, have
withdrawn as parties to this venture.
In addition, the following members
have changed their names: Koninklijke
Philips N.V. to Philips International
B.V.–IP&S, Eindhoven,
NETHERLANDS; and DTS, Inc., to
Xperi Corporation, Calabasas, CA.
No other changes have been made in
either the membership or planned
activity of the group research project.
Membership in this group research
project remains open, and UHD Alliance
intends to file additional written
notifications disclosing all changes in
membership.
On June 17, 2015, UHD Alliance filed
its original notification pursuant to
Section 6(a) of the Act. The Department
of Justice published a notice in the
Federal Register pursuant to Section
6(b) of the Act on July 17, 2015 (80 FR
42537).
The last notification was filed with
the Department on December 15, 2017.
A notice was published in the Federal
Register pursuant to Section 6(b) of the
Act on February 12, 2018 (83 FR 6051).
Patricia A. Brink,
Director of Civil Enforcement, Antitrust
Division.
[FR Doc. 2018–07129 Filed 4–6–18; 8:45 am]
BILLING CODE 4410–11–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Application: United States
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before May 9, 2018. Such persons
may also file a written request for a
hearing on the application on or before
May 9, 2018.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
DATES:
Administration, Attention: DEA Federal
Register Representative/DRW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for hearing must be
sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All request for hearing
should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/LJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DRW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
delegated to the Assistant Administrator
of the DEA Diversion Control Division
(‘‘Assistant Administrator’’) pursuant to
section 7 of 28 CFR part 0, appendix to
subpart R.
In accordance with 21 CFR
1301.34(a), this is notice that on March
1, 2018, United States Pharmacopeial
Convention, 12601 Twinbrook Parkway,
Rockville, MD, 20852 applied to be
registered as an importer of the
following basic classes of controlled
substances:
SUPPLEMENTARY INFORMATION:
sradovich on DSK3GMQ082PROD with NOTICES
Controlled substance
Drug code
Cathinone ........................................................................................................................................................................
Methaqualone ..................................................................................................................................................................
Lysergic acid diethylamide ..............................................................................................................................................
4-Methyl-2,5-dimethoxyamphetamine .............................................................................................................................
4-Methoxyamphetamine ..................................................................................................................................................
Codeine-N-oxide ..............................................................................................................................................................
Difenoxin ..........................................................................................................................................................................
Heroin ..............................................................................................................................................................................
Morphine-N-oxide ............................................................................................................................................................
Norlevorphanol ................................................................................................................................................................
Methamphetamine ...........................................................................................................................................................
Phenmetrazine .................................................................................................................................................................
Methylphenidate ..............................................................................................................................................................
Amobarbital ......................................................................................................................................................................
Pentobarbital ....................................................................................................................................................................
Secobarbital .....................................................................................................................................................................
Glutethimide .....................................................................................................................................................................
Phencyclidine ...................................................................................................................................................................
Phenylacetone .................................................................................................................................................................
Alphaprodine ....................................................................................................................................................................
Anileridine ........................................................................................................................................................................
Cocaine ............................................................................................................................................................................
VerDate Sep<11>2014
18:06 Apr 06, 2018
Jkt 244001
PO 00000
Frm 00051
Fmt 4703
Sfmt 4703
E:\FR\FM\09APN1.SGM
09APN1
1235
2565
7315
7395
7411
9053
9168
9200
9307
9634
1105
1631
1724
2125
2270
2315
2550
7471
8501
9010
9020
9041
Schedule
I
I
I
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
]]>Agencies
[Federal Register Volume 83, Number 68 (Monday, April 9, 2018)]
[Notices]
[Page 15175]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-07129]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National Cooperative Research and
Production Act of 1993--UHD Alliance, Inc.
Notice is hereby given that, on March 8, 2018, pursuant to Section
6(a) of the National Cooperative Research and Production Act of 1993,
15 U.S.C. 4301 et seq. (``the Act''), UHD Alliance, Inc. (``UHD
Alliance'') filed written notifications simultaneously with the
Attorney General and the Federal Trade Commission disclosing changes in
its membership. The notifications were filed for the purpose of
extending the Act's provisions limiting the recovery of antitrust
plaintiffs to actual damages under specified circumstances.
Specifically, Google, Inc., Mountain View, CA; Teledyne LeCroy, Elgin,
IL; and Synaptics, San Jose, CA, have been added as parties to this
venture.
Also, HDAnywhere Ltd., Malvern, UNITED KINGDOM; Quantum Data, Inc.,
Elgin, IL; and Sky UK Ltd., Isleworth, UNITED KINGDOM, have withdrawn
as parties to this venture.
In addition, the following members have changed their names:
Koninklijke Philips N.V. to Philips International B.V.-IP&S, Eindhoven,
NETHERLANDS; and DTS, Inc., to Xperi Corporation, Calabasas, CA.
No other changes have been made in either the membership or planned
activity of the group research project. Membership in this group
research project remains open, and UHD Alliance intends to file
additional written notifications disclosing all changes in membership.
On June 17, 2015, UHD Alliance filed its original notification
pursuant to Section 6(a) of the Act. The Department of Justice
published a notice in the Federal Register pursuant to Section 6(b) of
the Act on July 17, 2015 (80 FR 42537).
The last notification was filed with the Department on December 15,
2017. A notice was published in the Federal Register pursuant to
Section 6(b) of the Act on February 12, 2018 (83 FR 6051).
Patricia A. Brink,
Director of Civil Enforcement, Antitrust Division.
[FR Doc. 2018-07129 Filed 4-6-18; 8:45 am]
BILLING CODE 4410-11-P
